semaglutide oral fda Approves as the First Oral GLP-1 Pill Novo says it's submitted obesity

Walker, D

While not indicated specifically for hypertension treatment, Zepbound's dual GIP/GLP-1 receptor agonist mechanism produces metabolic improvements that may benefit patients with obesity and elevated blood pressure

Retatrutide has not received MHRA marketing authorisation and is not currently available on the NHS or via private prescription in the UK

Obesity itself is a major risk factor for cardiovascular disease, including coronary artery disease, heart failure, and arrhythmias

Specific amino acids like arginine, lysine, ornithine, and glycine can stimulate HGH release, which in turn promotes IGF-1 production

When I hit menopause, it felt like someone had secretly replaced my metabolism with a sloths